Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Formulation 1 solabegron · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Formulation 1 solabegron | EXPERIMENTAL | Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3. |
| Formulation 2 solabegron | EXPERIMENTAL | Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3. |
| Name | Type | Description |
|---|---|---|
| Formulation 1 solabegron | DRUG | - |
| Formulation 2 solabegron | DRUG | - |
Inclusion Criteria: * Body weight greater than or equal to 50 kg, inclusive, and body mass index (BMI) 18.0 - 32.0 kg/m2, inclusive * In good general health as determined by a thorough medical history and physical examination, ECG, vital signs, and clinical laboratory evaluation. Results of clinica...
Formulation 1 solabegron is an investigational small molecule being studied for use in healthy subjects and in patients with overactive bladder. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Formulation 1 solabegron is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical research to evaluate the safety and pharmacokinetics of this investigational drug.
Formulation 1 solabegron is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for any use. The Phase 1 trial has been completed, and the drug remains under clinical investigation.
Formulation 1 solabegron has one completed Phase 1 clinical trial registered as NCT02938507. This study evaluated the safety, tolerability, and pharmacokinetics of different orally administered formulations of solabegron in healthy male subjects, with a total enrollment of 24 participants.
Yes, Formulation 1 solabegron is a specific formulation of the drug solabegron. The clinical trial NCT02938507 was designed to compare different formulations of orally administered solabegron, with Formulation 1 being one of the versions tested in healthy subjects.